 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > POZEN Inc.
 |
POZEN Inc. |
 |
 |
 |
PROFILE |
 |
POZEN is a heady business. The development-stage company's primary product candidates, MT 100 and MT 300, are being developed as oral and injectable treatments, respectively, for migraine headaches. Other pharmaceutical products in the pipeline include MT 500, which blocks receptors in the brain that are implicated in migraines, and MT 400, a migraine treatment that combines two commercially available drugs. The company has a licensing agreement with Hoffmann-La Roche for MT 500 and plans to establish similar agreements with other pharmaceutical firms.
COMPETITION |
 |
Abbott Laboratories (ABT)
Interneuron Pharmaceuticals, Inc. (IPIC)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
Employees: 20
Revenue per employee: $5,000.00
KEY PEOPLE |
 |
John R. Plachetka
CEO
Matthew E. Czajkowski
CFO
CONTACT INFO |
 |
6330 Quadrangle Dr., Ste. 240
Chapel Hill, NC 27514
US
Phone: 919-490-0012
Fax: 919-490-5552
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |